Bristol-Myers Squibb Co
(LTS:0R1F)
$
54.48
-1.095 (-1.97%)
Market Cap: 109.81 Bil
Enterprise Value: 153.11 Bil
PE Ratio: 0
PB Ratio: 6.41
GF Score: 84/100 Bristol-Myers Squibb Co at Barclays Global Healthcare Conference - Fireside Chat Transcript
Mar 16, 2022 / 05:35PM GMT
Release Date Price:
$69.8
(+0.77%)
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst
Good afternoon, and welcome to the Barclays Global Healthcare Conference. My name is Carter Gould, senior biopharma analyst here at Barclays. Welcome. And next up is Bristol-Myers Squibb. We're really happy to have Bristol here, again, one of these companies that we've been looking forward to meet in person over the past 2 years. And joining from the company is the CMO and Head of Global Drug Development, Samit Hirawat. Samit, thank you very much for joining us today.
Samit Hirawat
Bristol-Myers Squibb Company - Executive VP & Chief Medical Officer of Global Drug Development
Thank you, Carter. Pleasure.
Questions & Answers
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst
And in contrast to many of your peers, you have a very active 2022 from a catalyst perspective. A lot of clinical data, a number of launches coming up, so no shortage of stuff to talk about today. And in fact, you had a very busy week
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot